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Abstract
Mitochondria are well-known cellular organelles widely studied in relation to a variety of disease 
states, including Alzheimer’s disease. With roles in several metabolic processes, numerous signal 
transduction pathways, and overall cell maintenance and survival, mitochondria are essential to 
understanding the inner workings of cells. As mitochondria are able to be utilized by diverse 
illnesses to increase the likelihood of disease progression, targeting specific processes in these 
organelles could provide beneficial therapeutic options.
Introduction
Mitochondria are double-membrane-bound organelles composed of an outer membrane 
(OM) and an inner membrane (IM), which is further constructed into compartments: the 
intermembrane space, the cristae interior, and the matrix. These organelles are central 
players in cellular function with roles in sustaining cell survival, maintaining energy 
metabolism, balancing reactive oxygen species (ROS), and mediating cell death pathways. 
Given their extensive role in cells, mitochondrial function and dysfunction has been 
examined in many diseases, including neurodegeneration. Studying the functions of 
mitochondria in diseased cells, in comparison with healthy cells, may elucidate the modified 
mechanisms and molecular components involved in specific disease states. Within this 
review, mitochondrial processes necessary for cell survival under normal conditions are 
discussed. Cell death pathways mediated by mitochondria are examined, with particular 
attention given to various components in view of their relevance in neurodegeneration, 
specifically Alzheimer’s disease (AD). Finally, current and prospective treatment strategies 
will be reviewed.
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Mitochondrial Roles in the Cell
Calcium Homeostasis
Mitochondria within the vicinity of cytosolic Ca2+ or organelle Ca2+ release sites rapidly 
take up ions through voltage dependent anion channels (VDACs) on the OM. Along the IM, 
Ca2+-sensitive uniporter channels pass ions into the matrix. Once inside a mitochondrion, 
Ca2+ levels accelerate adenosine triphosphate (ATP) production by stimulating 
dehydrogenases in the tricarboxylic acid (TCA) cycle (Figure 1.1). Ca2+ extrusion from 
intramitochondrial stores occurs primarily through cation exchangers. Also, a nonselective 
mitochondrial Ca2+-activated pore, termed the mitochondrial permeability transition pore 
(MPTP), takes in and extrudes Ca2+ ions during membrane permeability fluctuations. 
Although the MPTP is often connected with cell death elicited by Ca2+ overload and stress, 
Barsukova et al. demonstrated that it acts as a Ca2+ release channel under normal conditions 
[1] (Figure 1.7). Utilizing these influx and efflux mechanisms, mitochondria sustain Ca2+ 
levels within a narrow range for normal functioning of cellular processes.
Energy Metabolism
ATP manufacturing is dependent upon oxygen consumption, the TCA cycle, and the 
electron transport chain (ETC). Glucose enters glycolysis for conversion into pyruvate 
(Figure 1.2), which is subsequently fed into the TCA cycle (Figure 1.3). Enzymes of the 
TCA cycle are stimulated by mitochondrial Ca2+ to reduce nicotinamide adenine 
dinucleotide (NADH). Reduced NADH molecules are then targeted to the ETC to act as 
electron donors (Figure 1.4). Complex I accepts electrons from NADH, while complex II 
receives electrons from succinate. Electrons from complexes I and II transfer to complex III, 
and are incorporated into cytochrome c for delivery to complex IV. This last complex 
reduces oxygen to water and aids in ATP synthesis. Throughout the ETC process, protons 
are generated and used by ATP synthase (complex V) in the oxidative phosphorylation 
(OXPHOS) pathway to synthesize ATP from ADP and inorganic phosphate.
Oxidative Stress
While Ca2+ enhances ATP production via increasing ETC activity, more oxygen is reduced 
to water. This contributes to greater leakage of free electrons from the respiratory 
complexes, resulting in the formation of ROS. As a compensatory mechanism, Ca2+ also 
activates ROS scavenging enzymes, such as superoxide dismutase, to eradicate harmful 
oxidants. Healthy cells tightly regulate the balance between oxidants and antioxidants to 
prevent destructive consequences (Figure 1.5). However, deficiencies in ETC complex 
activities are associated with depleted energy stores and enhanced ROS production [2]. With 
low levels of ROS scavengers, harmful oxidants cause extensive damage. Healthy cells can 
prevent ROS-inflicted harm using uncoupling proteins (UCPs) (Figure 1.6), which block 
ROS formation and sequester Ca2+ in mitochondria.
Mitochondrial Permeability Transition Pore
The mitochondrial permeability transition is defined as an increase in IM permeability to 
molecules smaller than 1500 Daltons. In cells undergoing stress, this phenomenon is 
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initiated by opening of the MPTP, typically due to high levels of Ca2+ or ROS. MPTP 
induction can lead to loss of the transmembrane potential (ΔΨ), release of proapoptotic 
mediators, and cell death.
Cyclophilin D (CypD) has been identified as a modulatory component of the MPTP. Upon 
Ca2+ overload or oxidative stress in cells, CypD translocates from the matrix to the IM to 
initiate opening of the MPTP [3] (Figure 2.1 and 2.2). Along with CypD, two other channels 
have been strongly suggested as constituents of the MPTP. As a channel along the OM 
responsible for taking up ions into mitochondria, VDAC was a promising candidate. 
However, recent data suggests that VDAC is not a vital component of the MPTP structure 
[4]. Adenine nucleotide translocase (ANT) was another favorable contender, as it catalyzes 
the ATP/ADP exchange through the IM. Nevertheless, studies have shown that it is not 
essential for MPTP formation [5]. Thus, VDAC and ANT may be regulators of the MPTP, 
not physical units.
Mitochondrial-mediated Cell Death Pathways
Apoptosis can be initiated via two distinct pathways. The extrinsic route involves death 
receptors on the cell surface, whereas the intrinsic path originates in mitochondria (Figure 
2.1). Induction of apoptosis signaling stimulates initiator caspases, which activate 
executioner caspases for cleavage of death substrates. In mitochondria, antiapoptotic Bcl-2 
and Bcl-xL release tBid upon its activation by caspases. Proapoptotic Bax and Bak form a 
multidomain after stimulation from tBid, propelling the release of cytochrome c and other 
factors from the MPTP. The proapoptotic factors perpetuate the process, causing the 
organized collapse and shrinkage of the cell. Finally, the cell body is engulfed by nearby 
cells.
Necrosis can be launched in the event of cellular injury (Figure 2.2). Activation of death 
receptor adaptors leads to their translocation to the IM. This disrupts ANT-mediated 
ATP/ADP exchange, resulting in ATP depletion and ROS accumulation. Excessive levels of 
ROS and Ca2+ promote mitochondrial uncoupling and disruption of the ΔΨ via MPTP 
opening. Imbalances activate degradative enzymes that propagate the damage until the 
plasma membrane ruptures, leaking the cellular contents.
Alzheimer’s disease and Mitochondria
As the sixth leading cause of death in the United States, Alzheimer’s disease (AD) is 
expected to become more prevalent as the world population ages [6]. Since there are few 
available treatments for AD, it is essential to continue investigating this devastating disease. 
The amyloid hypothesis has propelled much AD research over the last decade concerning 
mitochondrial dysfunction in neurons.
AD is characterized by the loss of neuronal synaptic density and synapse number, and 
collection of abnormally folded amyloid tau proteins and amyloid-beta (Aβ)-peptides in the 
brain. These atypical proteins give rise to two hallmarks of AD pathology: neurofibrillary 
tangles and amyloid plaques. Prior to plaque formation, Aβ-peptides selectively accumulated 
within mitochondria promotes metabolic dysfunction [7], implicating mitochondria in AD 
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pathogenesis. As the disease progresses, Aβ impairs patients’ learning and memory [8]. 
Eventually, the accrual of Aβ is toxic to neuronal cells, ultimately leading to cell death. 
While the mechanism of Aβ toxicity remains to be clarified, it is thought to involve the 
overproduction of ROS, loss of Ca2+ homeostasis, and reduction in energy metabolism [9].
Disrupted Calcium Homeostasis in AD
Much evidence has indicated that exposure of Aβ causes an abnormal increase in 
intracellular Ca2+ levels in AD-affected neurons (Figure 3.1). Accumulation of large 
amounts of Ca2+ ions is well known to promote the induction of cell death. However, the 
mechanisms underlying Aβ-mediated disruption of calcium homeostasis are still largely 
unknown. It was reported that Aβ influences a variety of receptors that contain Ca2+ 
channels, resulting in Aβ-regulated intracellular Ca2+ concentrations during membrane 
depolarization and organelle release [10]. Moreover, Kawahara et al. recently proposed that 
Aβ-induced intracellular Ca2+ changes occur due to the formation of amyloid channels on 
neuronal cell membranes [11]. As Aβ-peptides have been shown to bind the membranes of 
wild type hippocampal neurons [12], and aggregation of Aβ leads to ion channel formation, 
the resulting unregulated channel would allow a continuous flow of Ca2+ ions into the cell, 
thus disrupting the cell’s Ca2+ balance. While this concept shows promise, additional studies 
need to be performed in AD models to verify that amyloid channels occur within diseased 
neurons.
Reduced Energy Metabolism in AD
Alterations in intracellular Ca2+ concentrations can profoundly impact cellular function. If 
not properly managed, Ca2+ levels inside mitochondria become toxic and can activate a 
series of events, which lead to cell death. A common occurrence in AD is decreased activity 
of many TCA cycle enzymes, correlating with diminished ATP production (Figure 3.2). 
Interestingly, Aβ has been observed to bind to the α-subunit of ATP synthase in amyloid 
precursor protein/presenilin-1 (APP/PS1) transgenic mice, thereby negatively regulating 
ATP production [13]. Furthermore, decreases in glucose metabolism have been reported in 
AD patients, suggesting that both major metabolic processes are compromised in the 
disease. While several studies confirm that energy metabolism is reduced in AD, the 
reasoning for this is unclear. One explanation for this energy deficiency is as a result of the 
side effect of ROS damage, as AD mitochondria display impairments in the ETC complexes 
leading to elevated ROS generation. In contrast, Sun et al. propose that the reduction in 
energy metabolism seen in AD is a protective response against lower levels of nutrients and 
oxygen [14]. Hence, AD-affected neurons may modify energy metabolism in a final effort to 
regain a healthy condition.
Elevated Oxidative Stress in AD
Besides changes in TCA cycle enzymes, AD mitochondria also display impairments in the 
ETC complexes leading to elevated ROS generation (Figure 3.3). Expression and functional 
variations have been observed in all complexes of multiple AD mouse models, though the 
most severe defects caused by Aβ are typically seen in complex IV [15]. Additionally, 
increased oxidative stress promotes the overexpression of β-secretase in brain tissue of both 
AD patients and triple-transgenic AD mice [16]. β-secretase is an enzyme responsible for Aβ 
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production, and thus elevation in its expression resulted in excessive amounts of Aβ-peptide. 
This becomes a feed-forward loop as Aβ aggregate formation enhances the generation of 
mitochondrial ROS by damaging the ETC, leading to even higher levels of oxidative stress. 
As seen from the vast amounts of data, the oxidative stress hypothesis is another well-
recognized theoretical mechanism for AD development. While the mechanisms underlying 
this concept are still under investigation, a conceivable method is through Aβ-induced 
mitochondrial dysfunction.
Modified MPTP Initiation in AD
Neuronal cell death in AD involves MPTP opening, chiefly due to Aβ toxicity. 
Modifications to MPTP constituents may have an impact on AD cells undergoing apoptosis. 
Indeed, interactions between CypD and Aβ-peptide have been visualized in diseased 
mitochondria, in which CypD-Aβ complexes promote organelle swelling and MPTP 
opening [17]. Our group postulates that in AD-affected mitochondria, Aβ-binding alcohol 
dehydrogenase (ABAD) disrupts CypD-Aβ interactions [18]. Once ABAD-Aβ complexes 
form, CypD is left uninhibited in the matrix. Due to Aβ-induced mitochondrial stress, CypD 
translocates to the IM to initiate MPTP-mediated cell death (Figure 3.4). This complex 
exchange of CypD for ABAD mediated by Aβ may hold promise as a therapeutic target, 
since ABAD is seen as a direct link between Aβ and mitochondrial toxicity in AD 
progression [19].
Likewise, ANT is thought to have a role in AD. Singh and colleagues propose that Aβ-
peptides localize to the IM near ANT channels, as strong ANT-Aβ interactions were 
observed using the STITCH database [20]. This interaction could possibly drive 
mitochondrial dysfunction in AD through the dysregulation of ATP/ADP transport. 
Similarly, VDAC is thought to be involved in AD as it is overexpressed in the hippocampus 
of AD transgenic mouse models [21] and postmortem brain tissue from AD patients [22]. 
Overall, further studies are needed to explore the roles of CypD, VDAC, and ANT in AD as 
the reasons behind these changes in expression and function remain elusive.
Adjusted Cell Death in AD
Much evidence has been generated in support of apoptosis-mediated cell death in AD 
pathogenesis (Figure 3.5). Aβ deposits have been found concurrently with increased caspase 
activity, amplified DNA damage, and altered apoptotic gene expression. Additionally, tissue 
from AD patients exhibit TUNEL-positive cells with apoptotic-like morphology, implicating 
apoptosis in the disease. However, other studies saw few or none of the traditional 
morphological characteristics of apoptosis, suggesting another pathway is also involved.
Although necrosis is only just beginning to be examined in AD, data already advocates that 
it plays a role in the disease. For instance, brain sections from patients with familial AD 
display the standard morphological features of necrotic cell death. This is further supported 
by studies in mice containing mutated presenilin-1, a gene linked to early-onset of familial 
AD; the animals exhibited increased susceptibility to necrosis induction. Although 
information on necrosis in AD is scarce, the current data indicate that necrotic cell death is 
important in familial AD, and perhaps sporadic AD as well.
Carlson et al. Page 5






















Treatment Strategies Targeting Mitochondria in AD
Since AD is largely dependent upon metabolic dysfunction, research targeting 
mitochondrial-driven events is being explored to slow disease advancement. A few drugs 
have been approved for AD treatment, including donepezil [23], rivastigmine [24], 
galantamine [25], and memantine [26]. While the current medications address the symptoms 
of AD, there is no evidence that they modify disease progression.
A group of insulin sensitizers, thiazolidinediones (TZDs), have been shown to increase 
glucose uptake, thereby adjusting cellular metabolism. Since glucose metabolism is 
generally reduced in AD, manipulating the process could be useful. Several TZDs are being 
investigated in relation to AD. Rosiglitazone prevents memory impairment in an AD mouse 
model [27] and exhibited promising results in Phase 2 studies. However, a recent Phase 3 
clinical trial saw no beneficial effect of rosiglitazone treatment in AD patients [28]. 
Pioglitazone also reduces cognitive defects and decreases Aβ deposits in AD transgenic 
mice [29]. Some small clinical studies have been performed in AD patients to evaluate the 
safety of pioglitazone [30]. At present, pioglitazone shows great promise as a drug candidate 
as it is able to penetrate the blood-brain barrier, unlike rosiglitazone.
Targeting of organelles and specific cellular processes is a relatively new approach to AD 
therapy. As mitochondrial dysfunction occurs early in the development of AD, therapeutic 
targeting of this organelle and its functions could counteract the molecular components 
driving AD progression. Another TZD drug candidate that specifically targets mitochondria, 
mitoglitazone (MSDC-0160), has completed Phase 2 clinical trials in AD patients [31]. 
Additionally, dimebon (latrepirdine), a non-selective antihistamine, enhances mitochondrial 
function in human neuroblastoma cells, in particular mitochondrial membrane potential and 
ATP production [32]. As dimebon alone failed to meet primary and secondary endpoints in 
Phase 3 studies [33], it was recently assessed in combination with donepezil. However, co-
treatment of dimebon with donepezil in Phase 3 AD clinical trials did not achieve substantial 
results for primary efficacy endpoints [34]. Taking the Aβ channel concept into 
consideration, two amphipathic pyridinium salts (MRS2481 and MRS2485) were found to 
provide protection in neuronal cells against Aβ neurotoxicity, essentially by blocking Aβ 
channel formation to regain Ca2+ homeostasis [35]. If the Aβ channel theory shows merit, 
animal studies using these salts will need to be performed to assess the applicability of the 
drugs in AD clinical trials.
MPTP induction in AD is also being examined, focusing particularly on the interactions of 
Aβ with CypD, ABAD, and perhaps ANT. Once CypD is released from Aβ complexes, it 
initiates MPTP opening. Ablation of CypD in AD transgenic mice results in enhanced 
mitochondrial function, and improved learning and memory [36, 37], suggesting that 
blocking CypD has potential for AD treatment. The addition of the pharmacological CypD 
inhibitor, cyclosporine A (CsA), to cultured neurons and isolated cortical mitochondria also 
attenuates Aβ-induced impairments in MPTP opening, and reduces mitochondrial and 
synaptic dysfunction [38]. Unfortunately, CsA lacks clinical significance in AD treatment 
because of its immunosuppressive effect of inhibiting calcineurin (a Ca2+-dependent protein 
phosphatase), severe renal toxicity, and inability to pass the blood-brain barrier. Also, 
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inhibition of ABAD-Aβ interactions in transgenic APP/ABAD mice reduces Aβ buildup and 
improves mitochondrial function [39]. Given the promising data, our group designed several 
small molecule inhibitors of ABAD for further study in AD [40]. Lastly, since the 
relationship between ANT and Aβ is fairly new, further inquiry may elucidate its 
involvement in MPTP-mediated cell death in AD.
Conclusion
Neuronal cells affected by AD undergo changes due largely to Aβ toxicity, many of which 
impact mitochondrial-driven processes for preparation toward cell death. With effective 
treatment options limited for AD, research has shifted to target-specific and/or concurrent 
therapeutic regimens. Since mitochondrial dysfunction is highly implicated in AD 
progression, targeting specific mitochondrial processes could enhance the susceptibility of 
diseased cells to available drugs at all stages of AD. This fresh approach toward disease 
treatment will likely increase the quantity and quality of therapeutic options for AD, and 
potentially open new avenues for use in other disease states as well.
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Figure 1. Mitochondrial function in normal cells
Under regular oxygen conditions, healthy cells primarily rely on mitochondrial OXPHOS 
for ATP production. 1) Ca2+ ions are taken up into a mitochondrion through VDACs and 
Ca2+-sensitive uniporter channels, and stimulate ATP generation. 2) Glucose is converted 
into pyruvate during glycolysis which is 3) imported into the mitochondrion for entry into 
the TCA cycle. 4) Reduced succinate and NADH molecules are used by the ETC complexes 
to power ATP generation. 5) ROS created along the ETC are balanced by antioxidants, such 
as superoxide dismutase (SOD), and 6) UCP channels. 7) Excess Ca2+ ions are expelled 
from the mitochondrion through the MPTP comprised of VDAC, ANT, and CypD.
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Figure 2. Mitochondrial-mediated cell death pathways in normal cells
In the event of cellular injury, a mitochondrion can signal cell death pathways for 
destruction of the whole cell. 1) Apoptosis (orange pathway) is initiated due to excessive 
Ca2+ and ROS levels. Bcl-2 is inhibited by BH3-only proteins, allowing Bax and Bak to 
interact, which induces MPTP opening for Ca2+ and cyto c release into the cytosol. These 
proapoptotic factors further propel the process until the cell collapses in an organized 
manner. 2) Necrosis (dark red pathway) results from ATP depletion and enhanced Ca2+ and 
ROS accrual. This leads to the loss of ΔΨ and eventual unplanned rupture of the cell.
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Figure 3. Altered mitochondrial processes during AD
In comparison with normal cells, unhealthy cells affected by AD contain dysfunctional 
mitochondria with altered processes. 1) Aβ enters the mitochondrion, causing disruption of 
Ca2+ homeostasis possibly via Aβ channel formation. 2) Ca2+ imbalance and Aβ 
accumulation cause diminished energy metabolism, leading to 3) increased ROS production. 
4) Ca2+ toxicity and enhanced ROS levels promote MPTP formation. ABAD binds to Aβ, 
displacing CypD from bound complexes. Once alone, CypD translocates to the IM and 
initiates MPTP opening. 5) Together, Aβ toxicity, high Ca2+ levels, and ROS accrual 
stimulate apoptotic cell death.
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Figure 4. Mitochondrial targets for treatment of AD
As mitochondrial processes are altered in AD, targeting dysfunctional pathways could lead 
to novel treatment regimens (labeled in purple). In AD cells, TZDs can be used to modulate 
glucose metabolism. Rosiglitazone and pioglitazone have also been shown to decrease Aβ 
accumulation within mitochondria. Mitoglitazone is thought to have similar properties, 
though further study is needed. ABAD inhibition blocks the formation of ABAD-Aβ 
complexes; this causes CypD to remain bound to Aβ, resulting in blockade of MPTP 
opening. Inhibition of CypD targets bound and unbound forms of CypD to prevent its 
translocation to the IM and MPTP induction. Dimebon increases ATP generation and 
stabilizes the mitochondrial membrane potential, thereby helping to prevent membrane 
depolarization and cell death. MRS2481 and MRS2485 have been observed to block Aβ 
channel formation, potentially resulting in re-attainment of Ca2+ homeostasis. Basically, 
preventing Aβ-mediated events in AD-affected mitochondria with the indicated therapeutics/
target areas could allow cells to regain a healthy condition.
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